How should I optimize the antihypertensive regimen for a patient with chronic kidney disease who is currently on hydralazine 100 mg twice daily, amlodipine 10 mg daily, and carvedilol 12.5 mg twice daily?

Optimizing Antihypertensive Regimen for CKD

You should immediately add an ACE inhibitor or ARB as first-line therapy, consider adding an SGLT2 inhibitor for cardiorenal protection, and potentially discontinue hydralazine as it provides no kidney-protective benefit in CKD. 1

Critical Missing Component: RAS Inhibition

Your patient is on three antihypertensives but lacks the most important drug class for CKD—a renin-angiotensin system inhibitor (ACEi or ARB). 1

• KDIGO strongly recommends (1B evidence) starting an ACEi or ARB for patients with CKD and moderately-to-severely increased albuminuria (A2-A3), regardless of diabetes status. 1
• Even without albuminuria data, it is reasonable to start RAS inhibition in CKD patients with hypertension. 1
• RAS inhibitors should be titrated to the highest approved tolerated dose because trial benefits were achieved at these doses. 1
• Monitor creatinine and potassium 2-4 weeks after initiation; continue therapy unless creatinine rises >30% within 4 weeks. 1

Add SGLT2 Inhibitor for Cardiorenal Protection

KDIGO now recommends (1A evidence) treating adults with CKD with an SGLT2 inhibitor if eGFR ≥20 ml/min/1.73m² with albuminuria ≥200 mg/g OR heart failure. 1

• For eGFR 20-45 with albuminuria <200 mg/g, SGLT2i is still suggested (2B evidence). 1
• SGLT2 inhibitors provide mortality and kidney function benefits independent of blood pressure lowering. 1
• Once started, continue even if eGFR falls below 20, unless not tolerated. 1

Reassess Current Medications

Hydralazine (100 mg BID)

• Hydralazine has no kidney-protective properties and is not a preferred agent in CKD. 2
• While IV hydralazine effectively lowers BP acutely (13 mmHg MAP reduction), oral hydralazine shows modest effect (6 mmHg MAP reduction). 3
• Consider discontinuing or reducing hydralazine once ACEi/ARB is optimized, as it adds no cardiorenal protection. 1, 2

Amlodipine (10 mg daily)

• Amlodipine is appropriate in CKD and does not worsen renal function. 4
• Dihydropyridine CCBs should not be used as monotherapy in proteinuric CKD but are appropriate in combination with RAS blockade. 2
• Continue amlodipine as adjunctive therapy. 2

Carvedilol (12.5 mg BID)

• Carvedilol is the preferred beta-blocker in CKD due to its vasodilating properties and alpha-1 blockade. 5, 6
• Carvedilol decreases renal vascular resistance, preserves renal blood flow, and may retard albuminuria progression. 5, 6
• The current dose (12.5 mg BID) is appropriate; target dose is 25 mg BID if tolerated and needed for BP control or heart failure. 7
• Continue carvedilol as it provides cardiorenal protection. 5

Blood Pressure Target

Target systolic BP <120 mmHg when tolerated, using standardized office measurement. 1

• This intensive target reduces cardiovascular risk in CKD. 1
• Avoid this target if patient has frailty, high fall risk, very limited life expectancy, or symptomatic orthostatic hypotension. 1

Recommended Optimization Algorithm

1. Check albuminuria status and eGFR to guide therapy intensity. 1

2. Start ACEi (e.g., lisinopril 10-40 mg daily) or ARB (e.g., losartan 50-100 mg daily):

   • Titrate to maximum tolerated dose. 1
   • Check creatinine and potassium in 2-4 weeks. 1
   • Accept creatinine increase up to 30%; manage hyperkalemia with potassium binders rather than stopping RASi. 1

3. Add SGLT2 inhibitor (e.g., dapagliflozin 10 mg or empagliflozin 10 mg daily) if eGFR ≥20. 1

4. Continue carvedilol 12.5 mg BID (consider uptitration to 25 mg BID if BP remains elevated or heart failure present). 7, 5

5. Continue amlodipine 10 mg daily as adjunctive therapy with RAS blockade. 4, 2

6. Taper and discontinue hydralazine once ACEi/ARB is at target dose and BP is controlled. 3, 2

Critical Monitoring Points

• Never combine ACEi + ARB + direct renin inhibitor (contraindicated in CKD). 1
• Monitor potassium closely; hyperkalemia can often be managed without stopping RASi. 1
• Continue ACEi/ARB even when eGFR falls below 30 ml/min/1.73m². 1
• Withhold SGLT2i during prolonged fasting, surgery, or critical illness due to ketosis risk. 1